CAS 461-82-5: 4-(Trifluoromethoxy)aniline

This Thermo Scientific Chemicals brand product was originally part of the Acros Organics product portfolio. Some documentation and label information may refer to the legacy brand. The original Acros Organics product / item code or SKU reference has not changed as a part of the brand transition to Thermo Scientific Chemicals.

This Thermo Scientific Chemicals brand product was originally part of the Alfa Aesar product portfolio. Some documentation and label information may refer to the legacy brand. The original Alfa Aesar product / item code or SKU reference has not changed as a part of the brand transition to Thermo Scientific Chemicals.

Amino-naphthols and other amino-phenols, their ethers and esters, other than those cont more than one kind of oxygen function; salts thereof nesoi

4-(Trifluoromethoxy)aniline

Stability Hygroscopic Applications 4-(Trifluoromethoxy)aniline is used in the synthesis of anticancer agents and antitumor medicaments. Also, its an intermediate in the production of labelled Riluzole (R510000), a neuroprotective agent. Modulates glutamatergic transmission. A glutamate release inhibitor. An anticonvulsant. Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package References Cilibrizzi, A., et al.: J. Med. Chem., 52, 5044 (2009), Verhaeghe, P., et al.: Bioorg. Med. Chem., 17, 4313 (2009), Chandregowda, V., et al.: Eur. J. Med. Chem., 44, 3046 (2009), Wahl, F., et al.: Eur. J. Pharmacol., 230, 209 (1993) Bensimon, G., et al.: N. Engl. J. Med., 330, 585 (1994); Piras, S. et al.: Eur. j. Med. Chem., 75, 169 (2014); Vyas, V. et al.: Eur. J. Med. Chem., 82, 385 (2014);

4-(Trifluoromethoxy)aniline is a reactive intermediate used in the synthesis of pharmaceuticals, dyes, and pesticides. It is prepared by reacting hydrogen fluoride with aniline in the presence of an acid catalyst. 4-(Trifluoromethoxy)aniline can be used to synthesize epoxyeicosatrienoic acids, which are potent anti-inflammatory agents. 4-(Trifluoromethoxy)aniline has been shown to have a pharmacokinetic profile that is similar to those of other fluoroquinolones, but has not been studied for clinical development.